Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Magazines
Fall Home Improvements
Women
Home & Realty
Outdoor Guide
Premier Home Style Tour 2024
Spring Home & Garden Show
Spring on the Road
Spring Wellness
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
2024 Readersâ Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Jazz Pharma Plc
(NQ:
JAZZ
)
126.67
+1.57 (+1.25%)
Streaming Delayed Price
Updated: 4:00 PM EST, Nov 22, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Jazz Pharma Plc
< Previous
1
2
3
4
5
6
7
8
9
...
12
13
Next >
4 Eye-Catching Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip
February 03, 2024
The growth-fueled Nasdaq Composite remains nearly 6% below its all-time high, which means amazing deals can still be found.
Via
The Motley Fool
Topics
Stocks
Exposures
US Equities
Wall Street Favorites: 3 Biotech Stocks With Strong Buy Ratings for January 2024
January 31, 2024
Biotech stocks are warming up in January and look to continue upward in 2024 as the economy improves. Here are three to check out.
Via
InvestorPlace
Topics
Economy
Exposures
Economy
Japanese University Will Research Marijuana's Medical Uses In First-Of-Its-Kind Collaboration With Australian Company
January 31, 2024
Via
Benzinga
Topics
Cannabis
Exposures
Cannabis
Evaluating Jazz Pharmaceuticals: Insights From 7 Financial Analysts
January 29, 2024
Via
Benzinga
2 Incredible Growth Stocks That Are Screaming Buys for 2024
January 22, 2024
These healthcare businesses are compelling buys for very different reasons.
Via
The Motley Fool
Decoding 6 Analyst Evaluations For Jazz Pharmaceuticals
January 03, 2024
Via
Benzinga
Analyst Ratings for Jazz Pharmaceuticals
November 29, 2023
Via
Benzinga
Jazz Pharmaceuticals: Q3 Earnings Insights
November 08, 2023
Via
Benzinga
4 Remarkable Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip
January 13, 2024
The growth-fueled Nasdaq Composite remains 7% below its all-time high, which means bargains can still be found.
Via
The Motley Fool
Topics
Stocks
Exposures
US Equities
US Stocks Set To Open Weaker As Traders Eye Key Main Street Events: Analyst Sees Buying Opportunity On 'Stunning' Earnings Expectations
January 03, 2024
Several market-moving catalysts, including the release of the Fed minutes, a Federal Reserve speech, and JOLTS data, could influence the day's market movement.
Via
Benzinga
Topics
Economy
Exposures
Interest Rates
7 Growth Stocks Poised to Thrive in a Post-Fed Pivot World
December 28, 2023
If the Federal Reserve loosens the monetary spigot, these companies could represent the growth stocks to buy now.
Via
InvestorPlace
Topics
Economy
Exposures
Interest Rates
Jazz Pharmaceuticals' Post-Traumatic Stress Disorder Drug Disappoints In Mid-Stage Study
December 22, 2023
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) announced top-line results from the Phase 2 trial of JZP150, an investigational small molecule selective fatty acid amide hydrolase (FAAH) inhibitor, on efficacy...
Via
Benzinga
3 No-Brainer Stocks to Buy With $500 Right Now
December 20, 2023
You don't need a mountain of cash to build wealth on Wall Street.
Via
The Motley Fool
Japan Approves Marijuana-Derived Medicines, Adopt 7-Year Prison Sentences For Recreational Use
December 06, 2023
Japan’s Parliament passed a bill Wednesday legalizing medical products derived from cannabis.
Via
Benzinga
Australian MPs Admit They Tried Cannabis, Signaling Policy Reform & Epidiolex For Seizures Approved In Canada
November 30, 2023
Around 8% of Australians are using medical marijuana either occasionally or regularly, according to a recent survey of 1,000 participants conducted by consumer insights company Antenna, reported...
Via
Benzinga
Topics
Cannabis
Exposures
Cannabis
3 Top-Rated Biotech Stocks That Analysts Are Loving Now
November 28, 2023
Investing in biotech stocks can be tricky, but analysts have bullish outlooks on these three, promising companies.
Via
InvestorPlace
Pot Stocks: Values Or Traps?
November 22, 2023
Pot stocks were the hottest thing around five years ago but after catching a bid during the pandemic, the stocks have now plunged to multi-year lows.
Via
Talk Markets
Topics
Cannabis
Exposures
Cannabis
3 Biotech Stocks That Could Be Millionaire Makers
November 22, 2023
Many biotech stocks offer exciting long-term growth prospects.
Via
The Motley Fool
Police Boss Turned Cannabis Reform Advocate, MMJ Legalization In Japan And More Global Updates
November 16, 2023
Medical Cannabis-Based Epidiolex Advances Through Japan's Legislature Earlier this week, Japanese policymakers gave the green light to a measure to legalize medical products derived from cannabis,...
Via
Benzinga
Topics
Cannabis
Exposures
Cannabis
3 No-Brainer Stocks to Buy With $200 Right Now
November 15, 2023
A modest amount of money can go a long way when it's invested in inexpensive, game-changing businesses.
Via
The Motley Fool
Autifony Announces Exclusive Global License and Collaboration Agreement with Jazz Pharmaceuticals on Two Ion Channel Targets for Neurological Disorders
November 14, 2023
From
Autifony Therapeutics Ltd
Via
Business Wire
7 Healthcare Stocks That Are Poised to Become the Next Unicorns
November 09, 2023
Discover healthcare stocks with remarkable potential for growth and "unicorn" status in the ever-evolving world of healthcare investments.
Via
InvestorPlace
Cannabis Cash Burn Concerns? Sell These 7 Overbought Stocks Now.
November 07, 2023
These overbought cannabis stocks are teetring on the edge as the sector is navigating through uncharted waters.
Via
InvestorPlace
Topics
Cannabis
Exposures
Cannabis
FDA Report On Its 50 Years In Cannabis Research, Signals A Boost In Medical Marijuana Prospects
November 03, 2023
Researchers with the Food and Drug Administration (FDA) reported Wednesday on the agency’s 50 years of experience with marijuana research. In an article titled “FDA’s 50
Via
Benzinga
Topics
Cannabis
Exposures
Cannabis
Product Safety
Ireland Reimburses Medical Marijuana-Based Drug For Chemotherapy-Induced Nausea And Vomiting
October 30, 2023
Althea Group Holdings Limited (ASX: AGH), an Australian manufacturer of cannabis-based medicines and recreational cannabis products confirmed that Ireland’s Primary Care Reimbursement...
Via
Benzinga
Topics
Cannabis
Exposures
Cannabis
Global Cancer Vaccines Market Share Is Expected To Reach $19.27 Billion By 2030
October 25, 2023
EQNX::TICKER_START (OTCPK:DTCFF),(CSE:DTC),(NASDAQ:JAZZ),(NASDAQ:EXEL),(NASDAQ:AMGN),(NASDAQ:REGN) EQNX::TICKER_END
Via
FinancialNewsMedia
Europe's High: UK Parents Need NHS Help For Daughter's Seizures, THC MMJ Flowers In Switzerland & More
October 24, 2023
Luxembourg: Medical Marijuana Shortage Due To Supplier Change
Via
Benzinga
Topics
Cannabis
Supply Chain
Exposures
Cannabis
Supply Chain
Cannabis Stocks Dip: How Rising Interest Rates Impact Your Portfolio
October 23, 2023
On Friday, cannabis stocks traded lower with the overall market. Marketfy analyst Michael Berger will be monitoring how the sector performs this week.
Via
Benzinga
Topics
Cannabis
Exposures
Cannabis
Europe's High: Irish GPs Against Pot, Switzerland-Spain Share Data On Cannabis Clubs & More
October 20, 2023
Denmark: Medical Marijuana Pilot Program Experience 90% Growth In 12 Months
Via
Benzinga
Topics
Cannabis
Exposures
Cannabis
Jazz Pharmaceuticals Explores Asset Sale Option, Possibly Cannabinoid Business: Report
October 20, 2023
Jazz Pharmaceuticals PLC (NASDAQ: JAZZ) is reportedly exploring strategic options comprising a potential sale.
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
12
13
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.